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Management of Possible Sexual, Injecting-Drug–Use,
or Other Nonoccupational Exposure to HIV, Including
Considerations Related to Antiretroviral Therapy
Public Health Service Statement 
Summary
The most effective methods for preventing human immunodeficiency virus
(HIV) infection are those that protect against exposure to HIV. Preventive behav-
iors include sexual abstinence, sex only with an uninfected partner, consistent
and correct condom use, abstinence from injecting-drug use, and consistent use
of sterile equipment by those unable to cease injecting-drug use. Some health-
care providers have proposed offering antiretroviral drugs to persons with
unanticipated sexual or injecting-drug–use HIV exposure to prevent transmis-
sion. However, because no data exist regarding the efficacy of this therapy for
persons with nonoccupational HIV exposure, it should be considered an
unproven clinical intervention. Health-care providers and their patients may opt
to consider using antiretroviral drugs after nonoccupational HIV exposures that
carry a high risk for infection, but only after careful consideration of the potential
risks and benefits and with a full awareness of the gaps in current knowledge.
To address concerns related to providing antiretroviral agents to persons af-
ter nonoccupational HIV exposure, CDC convened a meeting in July 1997 of
scientists, public health experts, clinicians, members of professional associa-
tions, representatives from industry, ethicists, and members of affected
communities. This report reviews the topics raised at the meeting, provides
background information on patient management options, and presents consid-
erations for antiretroviral therapy.
INTRODUCTION
The most effective methods for preventing human immunodeficiency virus (HIV)
infection remain those that protect against exposure to HIV. Antiretroviral therapy
should never replace adopting and maintaining behaviors that guard against HIV ex-
posure (e.g., sexual abstinence, sex only with an uninfected partner, consistent and
correct condom use, abstinence from injecting-drug use, and consistent use of sterile
equipment by those unable to cease injecting-drug use). Medical treatment after sex-
ual, injecting-drug–use, or other nonoccupational HIV exposure* is likely to be a
* In this report, a sexual exposure that can place a person at risk for HIV infection is defined as
a discrete penetrative sex act (e.g., acts involving the insertion of the penis into the vagina,
anus, or mouth) involving vaginal, anal, penile, or oral contact with the sex partner’s potentially
infectious body fluids, including substances that have been implicated in the transmission of
HIV infection (i.e., blood, semen, vaginal secretions, or other body fluids when contaminated
with visible blood).
A nonsexual, nonoccupational exposure (excluding perinatal exposures) that can place a
person at risk for HIV infection is defined as a percutaneous penetration (e.g., a needlestick,
injection, piercing, or cut with a sharp object); contact with mucous membranes; or contact
with skin (especially when the involved skin is chapped, abraded, or affected by dermatitis;
when the contact is prolonged; or when the involved area is extensive) and substances that
have been implicated in the transmission of HIV infection (i.e., blood, tissues, or other body
fluids when contaminated with visible blood).
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relatively ineffective method for preventing HIV infection compared with preventing
exposure in the first place. The Public Health Service (PHS) has recommended using
antiretroviral drugs to reduce the acquisition of HIV infection among persons exposed
in the workplace (e.g., accidental needlesticks received by health-care workers) (1,2 ).
Although health-care providers and others have proposed offering antiretroviral
drugs to persons with unanticipated sexual or injecting-drug–use HIV exposures (3,4),
no data exist regarding the effectiveness of such therapy for these types of expo-
sures.*
In July 1997, CDC sponsored the External Consultants Meeting on Antiretroviral
Therapy for Potential Nonoccupational Exposures to HIV. This meeting brought to-
gether scientists, public health experts, clinicians, members of professional
associations, representatives from industry, ethicists, and members of affected com-
munities to discuss concerns related to providing antiretroviral agents to persons
after nonoccupational HIV exposure. This report reviews the topics raised at the meet-
ing, discusses background information on patient management options, and presents
considerations for antiretroviral therapy.
THERAPY AFTER NONOCCUPATIONAL HIV EXPOSURE
Health-care providers may want to provide their patients with a system for
promptly initiating evaluation, counseling, and follow-up services after a reported sex-
ual, injecting-drug–use, or other nonoccupational HIV exposure that might put a
patient at high risk for acquiring infection. Sexual exposure also can put a patient at
risk for other sexually transmitted diseases (STDs) and pregnancy. Injecting-drug–use
exposure through shared injection equipment can put a patient at risk for acquiring
other viral infections (e.g., hepatitis B and hepatitis C). All persons evaluated for pos-
sible nonoccupational HIV exposure should be counseled to initiate, resume, or
improve risk-reduction behaviors to avoid future exposure and to prevent possible
secondary transmission until their current HIV infection status is determined.
CONSIDERATIONS FOR USING ANTIRETROVIRAL AGENTS
Decisions to provide antiretroviral agents to persons after possible nonoccupa-
tional HIV exposure to prevent the establishment of HIV infection must balance the
potential benefits and risks. Factors influencing the potential efficacy of this interven-
tion include the probability that the source contact is HIV-infected, the likelihood of
transmission by the particular exposure, the interval between exposure and initiation
of therapy, the efficacy of the drug(s) used to prevent infection, and the patient’s ad-
herence to the drug(s) prescribed.
Possible Benefits
The major potential benefit of antiretroviral postexposure prophylaxis is reducing a
person’s risk for acquiring HIV infection after exposure. Estimates differ for the trans-
*Information included in these recommendations may not represent Food and Drug Admini-
stration approval or approved labeling for the particular products or indications in question.
Specifically, the terms “safe” and “effective” may not be synonymous with the FDA-defined
legal standards for product approval.
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mission risk (if the person is not treated) after specific HIV exposures and the possible
effect of early treatment after such exposures.
Probability of Transmission From One HIV Exposure
HIV can be transmitted efficiently through blood transfusions: an estimated 95% of
recipients become infected from transfusion of a single unit of infected whole blood.
The per-contact probability of transmission from an HIV-infected source is much lower
for injecting-drug–use and sexual exposures. The risk for HIV transmission per epi-
sode of intravenous needle or syringe exposure is estimated at 0.67% (5 ). The risk per
episode of percutaneous exposure (e.g., a needlestick) to HIV-infected blood is esti-
mated at 0.4% (upper limit of 95% confidence interval [CI] = 0.8%) (6 ). The risk for HIV
transmission per episode of receptive penile-anal sexual exposure is estimated at
0.1%–3%; the risk per episode of receptive vaginal exposure is estimated at 0.1%–0.2%
(7 ). No published estimates of the risk for transmission from receptive oral exposure
exist, but instances of transmission have been reported (8,9 ).
Pathogenesis of Early HIV Infection
Information about the initial physiologic events after HIV exposure suggests that it
can take several days for infection to become established in the lymphoid and other
tissues. During this time, interventions to interrupt viral replication could represent an
opportunity to prevent an exposure from becoming an established infection (10,11 ) 
Studies of Antiretroviral Agent Use to Prevent HIV Infection in Animals
Attempts to protect animals with antiretroviral monotherapy after experimental
mucosal and intravenous (IV) exposures have produced various results (12 ). In stud-
ies to assess the efficacy of zidovudine (ZDV) administered after IV exposure to simian
immunodeficiency virus (SIV), the suppression or delay of viral replication was com-
mon but the prevention of infection was rare (13,14 ). Treatment initiated within 24
hours of exposure and continued for 28 days appeared to have a greater effect than
treatment initiated 72 hours after exposure. However, ZDV might not be the optimal
agent to demonstrate proof-of-concept because it has not demonstrated potent inhibi-
tory activity against SIV infection in macaques, even when treatment is initiated
before viral exposure (12,15 ). In another study in which a licensed antiretroviral drug
was administered to macaques, initiating stavudine (d4T) treatment at the time of IV
exposure to human immunodeficiency virus type 2 (HIV-2) resulted in a delay in the
onset of viremia and a reduction in viral load (16 ). Although protection from infection
was not observed, most of the treated animals exhibited sustained control of viral
replication and normal CD4+ cell levels for >1 year after receiving 16 weeks of drug
treatment. More compelling evidence of the efficacy of antiretroviral drugs for postex-
posure prophylaxis in animal models has been generated by using unlicensed
compounds. SIV infection was prevented in 100% of macaques when treatment in
phase I/II clinical trials with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA), a nu-
cleotide analogue, was started either 4 or 24 hours after IV inoculation and was
continued for 28 days (17 ). Protection was diminished if treatment was delayed >24
hours or if the treatment duration was reduced (18 ). In another recent study, mucosal
or IV infection of macaques with SIV was blocked when a 3-day treatment with the
nucleoside analogue 2’,3’-dideoxy-3’-hydroxymethyl cytidine (BEA-005) was initiated
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within 8 hours of viral exposure (19 ). Further corroborating the PMPA results, the
BEA-005 study demonstrated that increasing the time between exposure and treat-
ment initiation or decreasing the duration of treatment reduced protection.
The animal-model data demonstrate that antiretroviral agents administered after
SIV or HIV-2 exposure can prevent infection. However, extrapolating these results to
humans is problematic because of several factors, including differences between a)
the laboratory-adapted strains of SIV and HIV used in animal studies and the HIV
strains that circulate among persons; b) inoculum size; c) routes of inoculation or ex-
posure; d) time of treatment initiation; e) drug(s) used; f) treatment duration; and g)
host metabolism, host immunology, and other biological parameters. Animal studies
offer proof-of-concept and demonstrate the challenges to understanding the require-
ments for effective use of antiretrovirals to prevent HIV transmission in humans.
Studies of Antiretroviral Agent Use to Prevent HIV Infection in Humans
In 1995, investigators used case-control surveillance data from health-care workers
in France, Italy, the United Kingdom, and the United States to document that ZDV use
was associated with an 81% (95% CI = 48%–94%) decrease in the risk for HIV infection
after percutaneous exposure to HIV-infected blood (1,2,20,21 ). This study was a retro-
spective case-control study, rather than a prospective trial, which is the preferred
method of assessing clinical drug efficacy. Additional limitations were that a) the num-
ber of case-patients was small, b) the case-patients and controls came from separate
populations, c) some case-patients were reported anecdotally before formal surveil-
lance was established, and d) some details of exposures in case-patients were
obtained retrospectively, whereas information for controls was collected prospec-
tively. Although the health-care worker study demonstrated antiretroviral
effectiveness following percutaneous HIV exposure, some researchers have sug-
gested that the magnitude of the effect might be overestimated because of the
methodologic questions raised (22 ). ZDV has failed to prevent HIV infection in health-
care workers in 13 reported instances (23 ).
In a prospective, randomized controlled trial of ZDV administered to HIV-infected
women during pregnancy and labor and to their infants for 6 weeks postpartum, peri-
natal transmission was reduced 67% among those randomly assigned to the
treatment group compared with those in the control group, who received no an-
tiretroviral therapy. Results of multivariate analyses suggested that a prophylactic
effect on the fetus during antenatal, intrapartum, or postpartum exposure (24 ) could
account for some reduction in perinatal transmission. In a prospective trial of ZDV in
Thailand, perinatal HIV transmission was reduced 51% for women treated from 36
weeks’ gestation until delivery (25 ). Perinatal transmission despite use of ZDV pro-
phylaxis in pregnancy also has been reported (26 ).
Although these studies suggest that antiretroviral agents are potentially valuable
for treating HIV exposures in these settings, the data might not be directly relevant to
nonoccupational exposures. Health-care workers often are exposed to HIV in settings
where antiretroviral therapy can begin within 1–2 hours of exposure and where the
HIV status of the source patient usually can be determined quickly. These circum-
stances are unlikely for many nonoccupational exposures. The perinatal transmission
model also might not be directly relevant to nonoccupational exposures. If most peri-
natal infections occur at the time of delivery, the observed effectiveness of ZDV
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therapy could represent a preexposure not a postexposure effect. Despite the appar-
ent usefulness of antiretroviral agents in perinatal and occupational settings, it is
unclear whether these findings can be extrapolated to other settings. Further studies
are needed before one can conclude whether using antiretroviral agents to prevent
HIV infection after nonoccupational exposures is effective.
Possible Risks
Potential risks of antiretroviral postexposure prophylaxis include drug toxicity, re-
duced effectiveness of behavioral HIV-prevention measures, and the acquisition of
antiretroviral-resistant HIV strains. Also, the cost of medications could tax already
scarce public funds for antiretroviral agents for HIV-infected persons, which offer cost-
effectiveness and therapeutic benefit. Many insurers will not cover the cost of this
unproven therapy, so any possible benefit will be limited based on the patient’s ability
to pay. 
Side Effects and Toxicity of Antiretroviral Agents 
The frequency, severity, duration, and reversibility of side effects must be weighed
against the usefulness of antiretroviral agents for any patient. All antiretroviral agents
have been associated with side effects. Adverse events have been reported for per-
sons with advanced HIV disease (and longer treatment courses), but persons with less
advanced disease or those who are uninfected might have different experiences (27 ).
Many side effects can be managed symptomatically, but when the probability of trans-
mission is low, one must weigh this probability against the risk of a severe side effect.
Although the most common side effects are mild, studies have demonstrated that
50%–75% of health-care workers receiving ZDV alone for possible HIV exposure re-
ported one or more subjective complaints, and as many as 35% did not complete the
full course of therapy because of side effects (6,28,29 ). Preliminary information on
health-care workers receiving combination therapy for postexposure prophylaxis
demonstrated that 50%–90% reported subjective side effects and 24%–36% reported
side effects severe enough to discontinue therapy (30–33 ).
Many antiretroviral agents are associated with gastrointestinal side effects (e.g.,
nausea, vomiting, and diarrhea). In general, using combinations of agents has not
caused more instances of adverse effects, but serious drug interactions have occurred
when antiretrovirals were used with certain other medications. Current medications
must be evaluated before patients are prescribed any antiretrovirals, and health-care
providers must monitor patients closely for toxicities. Protease inhibitors recently
have been associated with the occurrence of lipid abnormalities (34–36 ), as well as
the development of diabetes mellitus, hyperglycemia, and diabetic ketoacidosis, and
they can exacerbate preexisting diabetes mellitus (27,37 ). Some health-care workers
using combination drugs for postexposure prophylaxis of occupational HIV exposure
have developed serious side effects—including nephrolithiasis, hepatitis, and pancy-
topenia—sometimes within 3 days of initiating therapy (31,32,38 ).
Behavior Changes Potentially Related to Prophylactic Antiretroviral Therapy
Some persons actively seek and repeatedly participate in high-risk behaviors (e.g.,
unprotected sex or needle-sharing injecting-drug use). The widespread availability of
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antiretroviral agents for treating possible nonoccupational HIV exposure could under-
mine public health efforts aimed at increasing and maintaining sexual and
injecting-drug–use behaviors that prevent HIV exposure. If persons perceive that
postexposure antiretroviral prophylaxis prevents HIV infection, they could increase
the frequency of risk behaviors or shift from lower-risk to higher-risk activities. If many
persons increase higher-risk behaviors, the widespread availability of antiretroviral
agents for treating HIV exposure paradoxically could increase the number of new in-
fections because the treatment’s effectiveness will be <100%. One study of 54 men
who had sex with men (recruited as part of an intervention counseling study) docu-
mented that 15% already had taken “a chance of getting infected when having sex”
because of the availability of new treatments. It is unclear whether this reported be-
havior was a response to the existence of antiretroviral postexposure prophylaxis or a
decreased fear of HIV disease because of the effectiveness of combination antiretrovi-
ral therapy (39 ).
Acquiring Antiretroviral-Resistant Virus
The use of antiretroviral agents after possible nonoccupational HIV exposure, par-
ticularly if a patient does not adhere to the prescribed drug treatment, poses the
theoretical risk that the patient could become infected with an antiretroviral-resistant
strain of HIV if postexposure prophylaxis fails to prevent infection. In nonoccupational
exposures, information regarding the antiretroviral-susceptibility patterns of the
source virus likely will not be known, making it difficult to tailor antiretroviral therapy
appropriately. 
Cost of Antiretroviral Postexposure Prophylaxis
A 28-day course of antiretroviral agents for a single possible exposure to HIV costs
an estimated $800 (range: $600–$1,000), depending on the agents used (4,40 ). This
cost generally is more per client than the cost of enrollment in intensive, behavioral,
HIV primary prevention programs designed to reduce the likelihood of future expo-
sures (41). If postexposure prophylaxis proves effective in reducing HIV transmission
after nonoccupational exposure, its cost dictates that use be restricted to high-risk
exposures to avoid compromising funds for more cost-effective behavior intervention
programs.
Uncertainties about key factors make it difficult to estimate the cost-effectiveness
of treating nonoccupational HIV exposure with antiretroviral drugs. However, recent
studies have used mathematical modeling to estimate cost-effectiveness ratios for
this treatment (42,43 ). These studies demonstrate that antiretroviral drugs could be
cost-effective for persons who engage in behaviors with high per-act infectivity (e.g.,
receptive anal intercourse) with persons known or likely to be HIV-seropositive. How-
ever, the drugs might not be cost-effective for treating exposures with low per-act
infectivity or involving partners at low risk for HIV infection.
EVIDENCE OF CURRENT PRACTICE
Some physicians have been asked to provide antiretroviral agents after certain sex-
ual exposures, including rape by an assailant of unknown HIV status and risk history
(44,45 ). Other reported exposures that could lead to requests for antiretroviral pro-
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phylaxis include injecting-drug–use relapse (4 ); condom breakage during anal sex be-
tween HIV-serodiscordant partners (46 ); nonconsensual sex in correctional
institutions (47 ); and breast-feeding of newborns by HIV-infected mothers (48 ). Be-
cause data have not been collected systematically in the United States, it is not
possible to estimate either the frequency of such requests or the actual use of an-
tiretroviral agents in these situations, or the adherence to or effectiveness of the
prescribed therapy. No summary information about what specific drug therapies are
being prescribed is available, although some physicians have based their practice on
published guidelines for treating occupational exposure (2 ).
Outside the United States, some guidelines are in use despite the absence of effec-
tiveness data. In Canada, the British Columbia Centre for Excellence in HIV/AIDS has
published A Guideline for Accidental Exposure to HIV, which recommends antiretrovi-
ral agents for rape victims (in addition to persons with occupational HIV exposure). To
allow postexposure antiretroviral therapy to be initiated quickly, the Centre provides a
free “starter kit” of 5 days of therapy with ZDV and lamivudine (3TC) to emergency
rooms where specialized teams care for the victims of sexual assault or to physicians
upon request.
COMMENTARY
Based on the knowledge of HIV pathogenesis and the possible benefit of an-
tiretroviral agents in preventing transmission (demonstrated in animal and human
studies), some physicians believe that antiretroviral agents are indicated for persons
with possible sexual, injecting-drug–use, or other nonoccupational HIV exposure (4 ).
However, PHS cannot definitively recommend for or against antiretroviral agents in
these situations because of the lack of efficacy data on the use of antiretroviral agents
in preventing HIV transmission after possible nonoccupational exposure. Efficacy and
effectiveness data and additional epidemiologic information are needed, including the
number of infections that could be averted by antiretroviral drugs, the number of per-
sons who would need treatment to avert one infection, the effects of antiretroviral
drug availability on risk behavior, and physician practices in prescribing antiretroviral
drugs.
Antiretroviral agents should not be used for persons with HIV exposures that have
a low risk of transmission (e.g., potentially infected body fluid on intact skin) or for
persons who seek care too late for the anticipated interruption of transmission (>72
hours after reported exposure). Physicians considering the use of antiretroviral agents
after a nonoccupational HIV exposure should recognize that benefits likely will be re-
stricted to situations in which the risk for infection is high, the intervention can be
initiated promptly, and adherence to the regimen is likely. In these instances, the phy-
sician and the patient should weigh the low per-act probability of HIV transmission
associated with the reported exposure against the uncertain effectiveness, potential
toxicities, and cost of antiretroviral drugs, as well as the patient’s anticipated adher-
ence to the therapy. If physicians decide to use antiretroviral agents, they should
consult with an HIV-care provider experienced with their use.
Postexposure antiretroviral therapy should never be administered routinely or
solely at the request of a patient. It is a complicated medical therapy, not a form of
primary HIV prevention. It is not a “morning-after pill,” but, if proven effective, can
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constitute a last effort to prevent HIV infection in patients for whom primary preven-
tion has failed to protect them from possible exposure.
CONSIDERATIONS IN CARING FOR PERSONS 
AFTER POTENTIAL NONOCCUPATIONAL EXPOSURE 
TO HIV WHEN DATA ARE INADEQUATE
Evaluation for STDs and Substance Abuse
Sexual activities associated with a risk for HIV transmission also are associated
with risk for unintended pregnancy and STDs (e.g., syphilis, gonorrhea, chlamydia, or
hepatitis B virus). Treatment for STDs should follow the CDC’s 1998 Guidelines for
Treatment of Sexually Transmitted Diseases (49 ), and victims of sexual assault should
receive additional evaluation and counseling (50 ). Women at risk for unintended preg-
nancy should be offered emergency contraception (51 ). Persons with possible HIV
exposure through percutaneous routes from sharing syringes or needles should be
assessed for hepatitis B and hepatitis C virus infections and considered for hepatitis B
virus vaccination. They also should be assessed and referred for appropriate sub-
stance abuse treatment.
HIV Evaluation and Management
Persons who report possible nonoccupational HIV exposure should be evaluated
for sexual and injecting-drug–use behavior that might lead to recurrent exposure. In
all situations, health-care providers should offer confidential risk-reduction counseling
(52 ) during initial and follow-up visits. Persons who have been sexually assaulted also
can be referred for anonymous or confidential voluntary counseling and testing within
72 hours of exposure to establish their HIV status at the time of the assault. Some
patients (e.g., those who have inconsistently or incorrectly used condoms or relapsed
into injecting-drug use) will need to be referred for intensive risk-reduction interven-
tions. Health-care providers evaluating persons for nonoccupational HIV exposure
should know where such services are available and help patients obtain them
promptly. 
Persons with nonoccupational HIV exposures should receive medical evaluations,
including HIV-antibody tests at baseline and periodically for at least 6 months after
exposure (e.g., at 4–6 weeks, 12 weeks, and 6 months). All persons evaluated for pos-
sible nonoccupational HIV exposure should be counseled to initiate or resume
protective behaviors to prevent additional exposure and to prevent possible secon-
dary transmission if they become infected while receiving antiretroviral therapy.
Considerations in Initiating Antiretroviral Therapy
Physicians considering the initiation of antiretroviral therapy in an attempt to re-
duce the risk for HIV infection in an exposed person should take the following steps in
consultation with an expert in the use of antiretroviral agents:
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• Evaluate the HIV status and risk-behavior history of the reported source of HIV
exposure.
• Provide medical care, supportive counseling, and prevention services to persons
who are determined to be HIV-infected when they seek care for a potential HIV
exposure.
• Evaluate the risk for HIV transmission (if there is convincing evidence of HIV in-
fection in the reported source patient). Physicians should determine the specifics
of the risk event (e.g., no condom, torn condom, whether receptive or insertive
partner, injection before or after others, number of persons sharing injection
equipment) and the presence or absence of factors that would modify risk (e.g.,
vaginal or anal tears or bleeding, visible genital ulcers or other evidence of an
active STD, or bleach treatment of injection equipment). 
• Determine the time elapsed between exposure and presentation for medical
care. Although animal studies indicate that antiretroviral agents are most effec-
tive within 1–2 hours of exposure and probably not effective when started later
than 24–36 hours after exposure, the interval during which therapy can be bene-
ficial for humans is unknown.
• Evaluate the frequency of HIV exposure. Uninfected persons who request an-
tiretroviral agents should be evaluated for sexual, injecting-drug–use, and other
behaviors that might lead to recurrent HIV exposures. Antiretroviral therapy is
not a replacement for adherence to behaviors that reduce the risk of HIV expo-
sure.
• Provide counseling and obtain informed consent. Because postexposure prophy-
laxis is an experimental therapy of unproven efficacy, informed consent should
be obtained and recorded in the medical charts of all persons prescribed an-
tiretroviral agents following nonoccupational exposure. Such consent should
document the patient’s understanding of a) the need to initiate or resume rele-
vant HIV risk-reduction behaviors (e.g., condom use and/or drug treatment); b)
the limited knowledge about the effectiveness and toxicity of antiretroviral treat-
ment for nonoccupational exposure; c) the known side effects of the medications
being prescribed; d) the name and phone number of a source for follow-up medi-
cal care; e) the frequency and timing of recommended follow-up HIV testing
(1,2,52 ); f) the signs and symptoms associated with acute HIV seroconversion;
and g) the need for adherence to prescribed medications to maximize efficacy
and reduce the risk for infection with a drug-resistant variant. The patient should
be told that physicians have diverse opinions about the use of antiretroviral
medications to treat possible nonoccupational HIV exposure and that PHS cannot
make definitive recommendations because of limited knowledge.
• Persons younger than age 16 years at the time of exposure should be evaluated
(before therapy is initiated) by pediatricians, family physicians, or other clinicians
expert in the specific medical needs, consent issues, and other factors involved
in their treatment, including the use of antiretroviral medicines for children and
adolescents. These factors can include the investigation of possible child sexual
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abuse, state-specific legal reporting requirements for situations that endanger
the welfare of minors, and local definitions of emancipation or other consent re-
quirements that define the circumstances under which children and adolescents
can give legal consent for their own medical care.
• HIV-exposed women who are pregnant (or could become so as a consequence of
the exposure event) should be evaluated before antiretroviral therapy is initiated
in consultation with obstetricians or other physicians expert in the care of HIV
infection during pregnancy to define which antiretroviral agent(s) would be ap-
propriate to the health of the woman and the fetus. Women should be counseled
on a) the limited data available about the short-term safety for the fetus and the
long-term safety of in utero antiretroviral exposure for the infant; b) the theoreti-
cal risks of suggested antiretroviral agents to the fetus during specific gestational
periods; and c) CDC’s recommendations regarding antiretroviral therapy for HIV-
infected pregnant women (53,54 ). No studies have been conducted on the safety
and effectiveness of antiretroviral agents in preventing HIV infection in unin-
fected women during attempts to conceive with HIV-infected partners, and this
therapy is not recommended for such use.
• If antiretroviral therapy is used, drug-toxicity monitoring should include a com-
plete blood count and renal and hepatic chemical function tests when therapy is
initiated and again 2 weeks after the patient begins to take the medications. If
subjective or objective toxicity is noted, physicians should consult with their ex-
perts on the need for further diagnostic studies and dose reduction or drug
substitution. It is possible that antiretroviral therapy during early HIV infection
could benefit the patient by reducing the initial level of viral replication (i.e., the
set point) and decreasing the extent of lymph node infiltration. Thus, for patients
with the highest-risk exposures, health-care providers may consider continuing
therapy until HIV test results are received from a specimen drawn after 28 days
of treatment. Patients should be monitored for signs and symptoms of acute HIV
infection during therapy. If such conditions develop, the patient should be tested
for HIV (p24 antigen, HIV viral load assays) during their 4-week course of therapy
with confirmation by standard HIV antibody tests. Persons who become infected
while taking antiretroviral therapy should be advised to continue taking the medi-
cation pending transfer to a health-care provider who specializes in long-term
HIV care (55,56 ).
RESEARCH NEEDS
Rigorously designed and executed studies are needed to evaluate the efficacy of
antiretroviral agents in preventing HIV infection after nonoccupational exposures.
Studies should include assessment of the rates of demand for antiretroviral therapy;
the proportion of requests that stem from high-risk exposures; the rates of acceptance
of therapy when offered; the patterns of drug prescriptions; the agents, doses, and
duration of therapy associated with efficacy; the levels of patient adherence when
therapy is prescribed; the rates of toxicity to drugs prescribed; and the costs of ther-
apy. In addition, HIV isolated from patients infected despite therapy should be
monitored to document the rates of acquisition of strains with genotypic or pheno-
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typic antiretroviral resistance to medications taken. When possible, patient strains
should be compared with HIV isolated from the reported source patients.
Studies also are needed to determine a) the distribution of knowledge about an-
tiretroviral postexposure prophylaxis among those with nonoccupational HIV
exposure, b) the effect of the availability of antiretroviral prophylaxis on HIV risk be-
haviors at the individual or community level, and c) the frequency of exposures for
which therapy might be recommended.
Animal studies designed to mimic nonoccupational exposure to HIV, the timing of
therapy initiation, and the antiretroviral drugs used for humans could provide addi-
tional information about the usefulness of drugs prescribed at specific intervals after
exposure and for defined durations. Drugs or drug combinations that demonstrate
promise for reducing retroviral transmission might be more easily documented in ani-
mal models.
SURVEILLANCE OF DOCUMENTED EXPOSURES
CDC is initiating a surveillance system to collect information about persons who
seek medical care after possible sexual, injecting-drug–use, or other nonoccupational
HIV exposures. No names or other personal identifiers of patients will be collected.
Health-care providers in the United States soon will be encouraged to report all per-
sons who receive or who are considered for antiretroviral agents for nonoccupational
HIV exposure to an anonymous registry that CDC is developing. The system will as-
sess utilization, effectiveness, and medication toxicity for those who receive treatment
through collection of the following information:
• characteristics of the reported exposure;
• use of antiretroviral medications, including dosage and duration;
• toxicity of and adherence to therapy;
• HIV seroconversion in patients who do and do not receive antiretroviral therapy
after exposure to a known HIV-infected source.
CDC will request follow-up information on patients whose nonoccupational HIV ex-
posure is documented and who gave consent to their physician for data reporting.
CDC also will assist with HIV testing when asked. 
Unusual or severe toxicity from antiretroviral drugs should be reported to the
manufacturer or the Food and Drug Administration ([800]-332-1088). The use of an-
tiretroviral drugs for pregnant women should be reported (without patient identifiers)
to the Antiretroviral Pregnancy Registry ([800]-258-4263).
For further information about the CDC-sponsored External Consultants Meeting on
Antiretroviral Therapy for Potential Nonoccupational Exposures to HIV, which took
place in July 1997, contact the National AIDS Clearinghouse ([800]-458-5231 or the
Internet website at <http://www.cdc.gov/nchstp/hiv_aids/media.htm>).
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CONCLUSION
Because of the lack of efficacy data for the use of antiretroviral agents to reduce HIV
transmission after a possible nonoccupational exposure, PHS is unable to recommend
for or against this therapeutic approach. If such therapy is attempted, health-care
providers must a) inform patients of the lack of data; b) select antiretroviral agents
carefully and monitor their side effects and toxicities closely; c) address their patients’
underlying risk-reduction needs (when applicable); and d) restrict the use of this ther-
apy to high-risk exposures (e.g., unprotected receptive anal or vaginal intercourse
with a known HIV-positive person). Research is needed to establish if and under what
circumstances antiretroviral therapy following nonoccupational HIV exposure is effec-
tive.
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